UK – Mapping of oesophageal cancer gene mutations leads to new drug targets

Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other cancer types.

The news, which was published in Nature Genetics, comes from Cancer Research UK researchers at the University of Cambridge, who used whole genome sequencing and whole exome sequencing to map mutations in OAC, the main subtype of oesophageal cancer in England.

The findings could provide options not currently available to patients beyond standard chemotherapy, radiotherapy or surgery and help to give more personalised therapies…